Guardant Health Inc (NASDAQ:GH) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,064,134 shares, an increase of 46.2% from the October 31st total of 727,769 shares. Based on an average daily volume of 360,287 shares, the days-to-cover ratio is currently 3.0 days. Approximately 3.8% of the shares of the company are sold short.
Several research firms recently weighed in on GH. William Blair began coverage on Guardant Health in a report on Monday, October 29th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. began coverage on Guardant Health in a report on Monday, October 29th. They issued an “overweight” rating and a $42.00 target price for the company. Cowen began coverage on Guardant Health in a report on Monday, October 29th. They issued an “outperform” rating for the company. Leerink Swann restated an “outperform” rating on shares of Guardant Health in a report on Monday, October 29th. Finally, Bank of America began coverage on Guardant Health in a report on Monday, October 29th. They issued a “neutral” rating and a $37.00 target price for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $39.50.
Shares of GH stock opened at $35.73 on Monday. Guardant Health has a 12 month low of $27.04 and a 12 month high of $44.25.
ILLEGAL ACTIVITY WARNING: “Guardant Health Inc (GH) Short Interest Update” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.com-unik.info/2018/12/03/guardant-health-inc-gh-short-interest-update.html.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.
Featured Article: How accurate is the Rule of 72?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.